SPONSORS

EHMSG gratefully acknowledges the support of the following sponsors

Platinum Sponsor

Logo RICHEN NEW.jpg

RICHEN EUROPE is the European operating branch of the RICHEN GROUP, a major international group of medical device manufacturers with a global commitment. The company specializes in developing the best solutions for patients in the field of gastroenterology. Over the years our R&D department has excelled in the design and development of high-performance safe equipment and reagents for the diagnosis of Helicobacter pylori infection. ​Since 2015, the Richen Group has been supporting the European Helicobacter & Microbiota Study Group (EHMSG) as Platinum Sponsor. URL: https://www.richeneurope.eu/

RICHEN_1stOpenCompetition_banner_2021.gi

The Richen group is always looking for new ways to increase the quality, reliability and certainty of diagnostic results as well as recognising the needs of its customers and working with research groups to further develop its research portfolio. Thanks to this philosophy, the Richen group is launching its first ever research competition, which aims to encourage and support early career medical researchers to conduct studies and generate results within a 1-year timeframe, enabling them to apply for more substantive competitive funding. URL: https://www.workshop.ehmsg.org/richen-competition

Educational Grant

TAKEDA  is supporting the conference with an independent medical educational grant URL: www.takeda.com

Silver Sponsors

Biocodex_corporate.png

BIOHIT OYJ is a Finnish biotechnology company operating on global markets. Our mission, “Innovating for Health”, describes our innovative products and services. Biohit works with scientific communities to produce new technologies, products and services based on research results and innovations that can be used to develop safe and cost-effective diagnostic tests for the early detection and prevention of diseases of the gastrointestinal tract. BIOHIT is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the United Kingdom. Biohit’s series B share (BIOBV) is quoted on NASDAQ OMX Helsinki, Small cap/Healthcare.  www.biohithealthcare.comwww.gastropanel.com

INFAI.jpg

INFAI is specialized in the transfer of advanced analytical technology in the field of medical diagnostics and the development of innovative pharmaceutical products. The company is a pioneer in the use of stable isotopes and NMR in gastroenterology, cardiovascular and metabolic diseases.

INFAI's laboratories in Bochum, Germany are equipped with state-of-the-art NMR and IR-MS instruments. These facilities are used for internal research and product development, but are also available for collaborative and contract research. In recent years, a range of non-invasive, highly efficient breath tests using stable isotopes has been developed. One of these tests is already approved and available for routine diagnosis of Helicobacter pylori infections. Other tests used to determine gastric emptying rate and exocrine pancreatic insufficiency will be available soon. URL: https://www.infai.de

Other Sponsors

YingYang+Sercon_NoStrapline_transparent.png